


Amendments to the Abstract


Kindly replace the abstract with the rewritten abstract as set forth on the attached separate sheet.

ABSTRACT OF THE DISCLOSURE

A process for preparing a compound represented by formula (IIa')



wherein Q represents group (i) as defined in the specification and R^2 to R^5 , R^{31} , R^{32} , and R^{52} are as defined in the specification, by (1) reacting a compound represented by formula (V)




wherein R^2 to R^5 and R^{52} are as defined in the specification, with a compound represented by $\text{R}^{31}\text{R}^{32}\text{C=O}$ wherein R^{31} and R^{32} are as defined in the specification; (2) reacting the compound prepared in (1) with a compound represented by $\text{R}^{71}\text{-C(=O)}\text{-R}^{72}$ wherein R^{71} and R^{72} each independently represent a chlorine atom, 4-nitrophenyl, or 1-imidazolyl; and (3) reacting the compound prepared in (2) with a compound represented by R^{33}OH wherein R^{33} is as defined in the specification.

ABSTRACT

5 Tricyclic triazolobenzazepine derivatives in the form of a prodrug are provided. The compounds according to the present invention are those represented by formula (I) and pharmaceutically acceptable salts and solvates thereof. The compounds are useful as antiallergic agents and exhibit excellent bioavailability.

10




15 wherein R¹ represents hydrogen, OH, alkyl or phenyl alkyl,

20 R², R³, R⁴, and R⁵ represent hydrogen, halogen, optionally protected hydroxy, formyl, optionally substituted alkyl, alkenyl, alkoxy or the like, and


Q represents a group selected from the following groups (i) to (iv), halogen, or alkoxy:

20




(i)

;




(ii)

;



(iii)

; and



(iv)